Laboratory of Child and Adolescent Psychiatry
Christoph Correll, MD ccorrell@lij.edu |
|
The Zucker Hillside Hospital has a long tradition of conducting treatment research in a broad range of child and adolescent psychiatric disorders. Current research efforts are led by Vivian Kafantaris, M.D. and Christoph Correll, M.D. Both are board-certified child and adolescent psychiatrists who engage in research and teaching full-time.
Dr. Kafantaris is a nationally recognized expert in the treatment of children and adolescents with bipolar disorder. She and her team have designed and completed several NIH-funded randomized controlled treatment trials in children and adolescents with bipolar disorder and attention deficit hyperactivity disorder with severe aggression. Current studies include:
Collaborative Lithium Trial (CoLT): Children and adolescents ages 7-17 years old diagnosed with Bipolar I Disorder-manic or mixed phase who can be treated on an outpatient basis are eligible to participate in this multi-phase, placebo-controlled study of the long-term efficacy and safety of lithium treatment. Participants will be monitored closely by an experienced team. This study is funded by the National Institute of Child Health and Development (NICHD).
Stepped Pharmacotherapy to Improve Self-Control Among Youth (SPICY): Children ages 6-12 years with a diagnosis of Attention Deficit Hyperactivity Disorder and either Oppositional Defiant Disorder or Conduct Disorder whose aggression or behavioral dyscontrol has not resolved on an adequate trial of stimulant monotherapy are eligible for screening. Participants will receive open treatment with an optimized dose of stimulant and parent training sessions with a research behavior therapist. If aggression remains a significant problem the child will be randomly assigned to have either divalproex sodium (Depakote), risperidone (Risperdal) or placebo added to their stimulant. The study includes regular medical and behavioral symptom monitoring by a child psychiatrist and a clinical child psychologist. This study is funded by the National Institute of Mental Health (NIMH).
A Parent-Provider Intervention to Improve ADHD Medication Adherence: Parents/guardians of children ages of 5 to 12 years old diagnosed with ADHD are recruited for this study. The aim is to improve ADHD medication adherence by helping clinicians more effectively communicate with parents and address specific barriers to treatment compliance. This study is funded by the National Institute of Mental Health (NIMH).
Dr. Correll is a nationally and internationally recognized expert in the area of pediatric psychopharmacology, antipsychotic efficacy and adverse effects, as well as early recognition and prevention of youth with emerging psychotic and mood disorders. Dr. Correll and his team are conducting several studies on beneficial effects and side effects of antipsychotics and mood stabilizers; symptomatic, diagnostic and functional outcomes of youth with psychiatric problems and on clinical and biological risk factors and protective factors predicting outcomes. These research projects involve naturalistic and randomized treatment, controlled and observational studies.
SATIETY study: children and adolescents (age 4-19 years) who start clinically decided antipsychotic treatment are followed in an observational cohort study design to assess the risks and benefits of these medications under real world conditions. Effectiveness, adverse effects and clinical and biological predictors of these effects are studied.
IMPACT study (sponsor: National Institute of Mental Health): children and adolescents (age 8-17 years) who have gained at least 10% of their body weight over the past 12 months on an antipsychotic and who are overweight are randomized to up to 6 months of open treatment of a) healthy lifestyle instruction alone or b) addition of metformin or c) a switch to a lower risk antipsychotic.
STRATEGY study: children and adolescents (age 10-19 years) who are either starting antipsychotic treatment for the first time ever, or who have gained at least 10% of their body weight over the past 12 months while treated with an antipsychotic are randomized to 3 months of open treatment of a) healthy lifestyle instruction alone or b) addition of metformin.
Adolescent Mood Disorder and Psychosis study: children and adolescents (age 12-18 years) who have a clinical diagnosis of a mood or psychotic disorder are interviewed to comprehensively characterize their psychiatric problems and followed in an observational cohort design to assess symptomatic and functional outcomes over time.
Select Publications for Christoph Correll:
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic Risk of Atypical Antipsychotics During First-Time Use in Children and Adolescents. JAMA – in press.
Correll CU, Malhotra AK, Saurabh K, McMeniman M, Kane JM: Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160(11):2063-5.
Kane, JM, Barrett EJ, Casey DE, Correll CU, Gelenberg AJ, Klein S, Newcomer JW: Metabolic effects of treatment with atypical antipsychotics. J Clin Psychiatry 2004; Nov;65(11):1447-55
Saito E, Correll CU, Gallelli K, Parikh U, McMeniman M, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adol Psychopharmacol 2004;14(3):350-8.
Straker D, Correll CU, Kramer-Ginsberg E, Saint-Vil R, Abdulhamid N, Koshy F, Rubens E, Kane JM, Manu P: Cost-effective screening for metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005; 162: 1217-21.
Correll CU, Penzner JB, Parikh UH, Mughal TB, Javed T, Carbon M, Malhotra AK: Recognizing and Monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents. Child Adolesc Psychiatr Clin N Am. 2006 Jan;15(1): 177-206.
Correll CU, Frederickson AM, Kane JM, Manu P: Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs. J Clin Psychiatry 2006;67;4:575-583
Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45(7): 771-791
Correll CU, Frederickson AM, Kane JM, Manu P: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007 Jan;89(1-3): 91-100.
Correll CU, Harris JL, Pantaleon Moya RA, Frederickson AM, Kane JM, Manu P: Low-density lipoprotein cholesterol in patients treated with atypical antipsychotics: Missed targets and lost opportunities. Schizophr Res. 2007 April; 92:103-7.
Select Publications for Vivian Kafantaris:
Kafantaris V, Coletti DJ, Dicker R, Padula G, Kane JM. Lithium treatment of acute mania in adolescents: A large open trial. J Am Acad Child Adolesc Psychiatry 42:1038-1045, 2003.
Kafantaris V, Coletti DJ, Dicker R, Padula G, Pleak RR, Alvir J, Kane JM. Lithium treatment of acute mania in adolescents: A placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry 43: 984-993, 2004.
Coletti D, Leigh E, Gallelli K, Kafantaris V: Patterns of adherence to treatment in adolescents with bipoldisorder J. Child Adolesc Psychopharmacol 15: 913-917, 2005.
Findling RL, Frazier JA, Kafantaris V, Kowatch R, McClellan J, Pavuluri M, Sikich L, Hlastala S, Hooper S, Demeter CA, Bedoya D, Brownstein B, Taylor-Zapata P. The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation. Child and Adolescent Psychiatry and Mental Health 2008 Aug 12;2 (1):21 PMCID: PMC2531078.
Kafantaris V, Kingsley P, Ardekani B, Saito E, Lencz T, Lim K, Szeszko, PR. Lower orbital frontal white matter integrity in adolescents with bipolar I disorder. J Am Acad Child Adolesc Psychiatry 48:79-86, 2009. PMCID: PMC19050654.
Blader JC, Schooler NR, Jensen PS, Pliszka SR, Kafantaris V. Adjunctive divalproex sodium vs. placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry, 2009 In press.